Combining Oncolytic Adenovirus with Chemotherapy for Osteosarcoma Treatment
Author Information
Author(s): Graat H C A, Witlox M A, Schagen F H E, Kaspers G J L, Helder M N, Bras J, Schaap G R, Gerritsen W R, Wuisman P I J M, van Beusechem V W
Primary Institution: VU University Medical Center
Hypothesis
Can the combination of oncolytic adenovirus Ad5-Δ24RGD with doxorubicin or cisplatin enhance treatment efficacy for osteosarcoma?
Conclusion
The combination treatment of oncolytic adenovirus and chemotherapy showed additive to synergistic effects on osteosarcoma cell lines but not on primary cell cultures.
Supporting Evidence
- Combination treatment was found to be synergistic in some osteosarcoma cell lines.
- Primary osteosarcoma samples showed limited response to combination treatment.
- Delayed addition of chemotherapy did not improve the efficacy of the combination treatment.
Takeaway
Researchers tested a new virus treatment combined with chemotherapy for bone cancer, finding it worked well in lab-grown cancer cells but not as effectively in actual patient samples.
Methodology
The study involved testing the effects of the oncolytic adenovirus Ad5-Δ24RGD in combination with doxorubicin or cisplatin on osteosarcoma cell lines and primary cell cultures.
Potential Biases
Potential bias in the selection of cell lines and primary samples may affect the generalizability of the results.
Limitations
The study's findings may not fully translate to clinical settings due to differences in cell line and primary cell responses.
Participant Demographics
The study included eight primary osteosarcoma samples from three patients, with varying p53 statuses and ages ranging from 6 to 25 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website